How much revenue did SI-BONE generate this year?
SI-BONE has achieved a revenue of 168.35 M USD this year.
SI-BONE Revenue 2024
SI-BONE Revenue
168.35 M USD
Ticker
SIBN
ISIN
US8257041090
WKN
A2N7LY
In 2024, SI-BONE's sales reached 168.35 M USD, a 21.21% difference from the 138.89 M USD sales recorded in the previous year.
The SI-BONE Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2026e | 231.28 | 47,31 |
| 2025e | 195.46 | 55,98 |
| 2024e | 168.35 | 65,00 |
| 2023 | 138.89 | 78,78 |
| 2022 | 106.4 | 85,24 |
| 2021 | 90.2 | 88,36 |
| 2020 | 73.4 | 87,87 |
| 2019 | 67.3 | 89,90 |
| 2018 | 55.4 | 91,16 |
| 2017 | 48 | 89,38 |
| 2016 | 42.1 | 87,65 |
| 2015 | 41.2 | 86,89 |
| 2014 | 40.1 | 83,79 |
| 2013 | 49 | 91,22 |
SI-BONE Revenue, EBIT, Net Income US8257041090 · A2N7LY
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into SI-BONE, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by SI-BONE from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects SI-BONE’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of SI-BONE. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into SI-BONE’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing SI-BONE’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on SI-BONE’s growth potential.
SI-BONE Revenue, EBIT and net profit per share
| Date | SI-BONE Revenue | SI-BONE EBIT | SI-BONE Net Income |
|---|---|---|---|
| 2026e | 231.28 M undefined | -23.56 M undefined | -21.22 M undefined |
| 2025e | 195.46 M undefined | -35.86 M undefined | -33.05 M undefined |
| 2024e | 168.35 M undefined | -42.98 M undefined | -40.04 M undefined |
| 2023 | 138.89 M undefined | -46.93 M undefined | -43.34 M undefined |
| 2022 | 106.4 M undefined | -59.6 M undefined | -61.3 M undefined |
| 2021 | 90.2 M undefined | -51.7 M undefined | -56.6 M undefined |
| 2020 | 73.4 M undefined | -38.6 M undefined | -43.7 M undefined |
| 2019 | 67.3 M undefined | -36 M undefined | -38.4 M undefined |
| 2018 | 55.4 M undefined | -12 M undefined | -17.5 M undefined |
| 2017 | 48 M undefined | -17.4 M undefined | -23 M undefined |
| 2016 | 42.1 M undefined | -17.6 M undefined | -20.6 M undefined |
| 2015 | 41.2 M undefined | -26.4 M undefined | -28.2 M undefined |
| 2014 | 40.1 M undefined | -26.3 M undefined | -27.8 M undefined |
| 2013 | 49 M undefined | -5.3 M undefined | -6.2 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2013 | 49 M USD | -5.3 M USD | -6.2 M USD |
| 2014 | 40.1 M USD | -26.3 M USD | -27.8 M USD |
| 2015 | 41.2 M USD | -26.4 M USD | -28.2 M USD |
| 2016 | 42.1 M USD | -17.6 M USD | -20.6 M USD |
| 2017 | 48 M USD | -17.4 M USD | -23 M USD |
| 2018 | 55.4 M USD | -12 M USD | -17.5 M USD |
| 2019 | 67.3 M USD | -36 M USD | -38.4 M USD |
| 2020 | 73.4 M USD | -38.6 M USD | -43.7 M USD |
| 2021 | 90.2 M USD | -51.7 M USD | -56.6 M USD |
| 2022 | 106.4 M USD | -59.6 M USD | -61.3 M USD |
| 2023 | 138.89 M USD | -46.93 M USD | -43.34 M USD |
| 2024e | 168.35 M USD | -42.98 M USD | -40.04 M USD |
| 2025e | 195.46 M USD | -35.86 M USD | -33.05 M USD |
| 2026e | 231.28 M USD | -23.56 M USD | -21.22 M USD |
SI-BONE stock margins US8257041090 · A2N7LY
The SI-BONE margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SI-BONE. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SI-BONE.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the SI-BONE's sales revenue. A higher gross margin percentage indicates that the SI-BONE retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the SI-BONE's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the SI-BONE's total revenue generated. When comparing the revenue margin year over year, investors can gauge the SI-BONE's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the SI-BONE. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the SI-BONE's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
SI-BONE Margin History
| SI-BONE Gross margin | SI-BONE Profit margin | SI-BONE EBIT margin | SI-BONE Profit margin |
|---|---|---|---|
| 2026e | 78.78 % | -10.19 % | -9.18 % |
| 2025e | 78.78 % | -18.34 % | -16.91 % |
| 2024e | 78.78 % | -25.53 % | -23.78 % |
| 2023 | 78.78 % | -33.79 % | -31.2 % |
| 2022 | 85.24 % | -56.02 % | -57.61 % |
| 2021 | 88.36 % | -57.32 % | -62.75 % |
| 2020 | 87.87 % | -52.59 % | -59.54 % |
| 2019 | 89.9 % | -53.49 % | -57.06 % |
| 2018 | 91.16 % | -21.66 % | -31.59 % |
| 2017 | 89.38 % | -36.25 % | -47.92 % |
| 2016 | 87.65 % | -41.81 % | -48.93 % |
| 2015 | 86.89 % | -64.08 % | -68.45 % |
| 2014 | 83.79 % | -65.59 % | -69.33 % |
| 2013 | 91.22 % | -10.82 % | -12.65 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2013 | 91.22 % | -10.82 % | -12.65 % |
| 2014 | 83.79 % | -65.59 % | -69.33 % |
| 2015 | 86.89 % | -64.08 % | -68.45 % |
| 2016 | 87.65 % | -41.81 % | -48.93 % |
| 2017 | 89.38 % | -36.25 % | -47.92 % |
| 2018 | 91.16 % | -21.66 % | -31.59 % |
| 2019 | 89.9 % | -53.49 % | -57.06 % |
| 2020 | 87.87 % | -52.59 % | -59.54 % |
| 2021 | 88.36 % | -57.32 % | -62.75 % |
| 2022 | 85.24 % | -56.02 % | -57.61 % |
| 2023 | 78.78 % | -33.79 % | -31.2 % |
| 2024e | 78.78 % | -25.53 % | -23.78 % |
| 2025e | 78.78 % | -18.34 % | -16.91 % |
| 2026e | 78.78 % | -10.19 % | -9.18 % |
SI-BONE Aktienanalyse
What does SI-BONE do?
SI-BONE Inc. is an innovative medical technology company based in Santa Clara, California. It was founded in 2008 by a group of orthopedic surgeons, engineers, and entrepreneurs who aimed to improve the treatment of lower back pain. The company is now globally recognized and specializes in the development and marketing of implants for the treatment of pain and discomfort in the pelvic and back areas. SI-BONE focuses on the treatment of pain and discomfort in the pelvic and back areas, offering a range of products for this purpose. The company's main focus is on the development of innovative implants that can be used minimally invasively, with the goal of providing patients with quick recovery and improved quality of life. The flagship product of SI-BONE is the iFuse implant. This implant is used in patients with chronic lower back pain caused by instability of the spine or pelvis. The iFuse implant stabilizes the pelvis and thereby reduces the pain originating from the unstable joint region. The iFuse implant has been FDA approved and is now available in over 40 countries worldwide. In addition to the iFuse implant, SI-BONE also offers a variety of other products tailored to the needs of physicians and patients. These include implantable instruments and consumables such as bone screws or arthroscopy needles. SI-BONE is a publicly traded company listed on NASDAQ under the ticker symbol "SIBN." The company's business model is based on providing innovative products to physicians and hospitals that optimize the treatment of back pain. To achieve this, SI-BONE works closely with leading industry professionals to enable optimal treatment of back pain. SI-BONE has established itself as a strong, innovative company specializing in minimally invasive implants in the field of pain therapy. Through close collaboration with physicians and specialists and investment in research and development of cutting-edge technologies, SI-BONE aims to continue growing and achieve a leading position in the field of pain therapy. SI-BONE ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding SI-BONE's Sales Figures
The sales figures of SI-BONE originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing SI-BONE’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize SI-BONE's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in SI-BONE’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about SI-BONE stock
How much was the turnover of the company SI-BONE compared to the previous year?
The revenue of SI-BONE has increased by 21.21% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of SI-BONE?
The revenue of SI-BONE is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of SI-BONE measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of SI-BONE so important for investors?
The revenue of SI-BONE is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does SI-BONE pay?
Over the past 12 months, SI-BONE paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SI-BONE is expected to pay a dividend of 0 USD.
What is the dividend yield of SI-BONE?
The current dividend yield of SI-BONE is .
When does SI-BONE pay dividends?
SI-BONE pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of SI-BONE?
SI-BONE paid dividends every year for the past 0 years.
What is the dividend of SI-BONE?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is SI-BONE located?
SI-BONE is assigned to the 'Health' sector.
Wann musste ich die Aktien von SI-BONE kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of SI-BONE from 7/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/16/2024.
When did SI-BONE pay the last dividend?
The last dividend was paid out on 7/16/2024.
What was the dividend of SI-BONE in the year 2023?
In the year 2023, SI-BONE distributed 0 USD as dividends.
In which currency does SI-BONE pay out the dividend?
The dividends of SI-BONE are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The SI-BONE stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von SI-BONE
Our stock analysis for SI-BONE Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SI-BONE Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
